# Asparaginase

NOT RECOMMENDED AS AN ESSENTIAL MEDICINE

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

EMLc | ATC codes: L01XX02

| | |
|---|---|
| **Indication** | Unspecified malignant neoplasms of unspecified sites ICD11 code: 2D4Z |
| **Medicine type** | Biological agent |
| **List type** | Complementary |
| **Formulations** | Powder for injection: 10 000 IU in vial. |
| **EML status history** | First added in 1993 (TRS 850)<br>Changed in 2007 (TRS 950)<br>Removed in 2015 (TRS 994) |
| **Sex** | All |
| **Age** | Also recommended for children |
| **Therapeutic alternatives** | The recommendation is for this specific medicine |
| **Patent information** | Patents have expired in most jurisdictions<br>Read more about patents. |
| **Tags** | Cancer Biological |
| **Wikipedia** | Asparaginase |
| **DrugBank** | Asparaginase |

## Summary of evidence and Expert Committee recommendations

As part of the comprehensive review of cancer medicines undertaken by the Expert Committee in 2015, listing of asparaginase was reviewed and specific indications for its use were recommended. Refer to the 2015 recommendation(s) for asparaginase for more information.